CINQAIR® (reslizumab) Injection – About Asthma Control
A program supporting CINQAIR® (reslizumab) Injection patients
video-placeholder-01.png
CINQAIR - Teva Pharmaceutical Industries Limited Trademark Registration
Help eligible, commercially insured patients save on out-of-pocket costs for CINQAIR*
Clinical Efficacy Guidelines
Israeli Pharma gets FDA Approval for Asthma Antibody
Cinqair (reslizumab)- Asthma- by Saro Arakelians, PharmD- Episode # 123 - YouTube
Reslizumab | New Drug Approvals
Medication Detail
hcp.cinqair.com
CINQAIR® (reslizumab) Injection – About Asthma Control
Flopped trials dash Teva's hopes of battling GSK, AZ with subcutaneous Cinqair | Fierce Pharma
Chest Medicine Made Easy-Dr Deepu: FDA approves Injectable drug for uncontrolled Asthma
Rx Item-Cinqair (Reslizumab) 10Mg/Ml Inj Sinle Use Vial 10Ml By Teva Respiratory
FDA Approves Cinqair To Treat Severe Asthma - Pharmacy Practice News
Dosing and Administration
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
CINQAIR® (reslizumab) Injection – About Asthma Control
Attachment: Product Information: Reslizumab
Subcutaneous Cinqair results add to Teva's troubles
New Drug Product: Cinqair - MPR
How patients use CINQAIR® (reslizumab) Injection Cost Support Program Card
